Study explores fertility hopes after cancer in young women
NCT ID NCT04678414
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study surveys women aged 18-45 diagnosed with gynecological or breast cancer to understand how they think about having children after treatment. Researchers aim to gather insights that could help future patients and survivors make informed choices about cancer treatment and family planning. The study involves focus groups, surveys, and telephone interviews with participants from MD Anderson and the California Cancer Registry.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide better information to help young cancer survivors make informed decisions about fertility and family planning.
- What could go wrong
- This is an observational survey study, not a treatment trial. It may not lead to direct medical advances, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- What raises endometrial cancer risk in black women? a study digs in
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Fasting during chemo: a new way to boost treatment?
- Can a Two-Antibody combo outsmart advanced cancer?